HOXB8 and Arthritis: Accordingly, GSK-J4 treatment of our ER-Hoxb8 monocytes reduced expression of the proinflammatory alarmins S100a8 and S100a9, which have been shown to drive the inflammatory process of arthritis (van Lent et al., 2012).